sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate
生物活性靶点体外研究体内研究 用途与合成方法 MSDS sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate价格(试剂级) 上下游产品信息
| 中文名称 | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate |
|---|---|
| 中文同义词 | 贝拉前列素钠盐(非对映异构体混合物);(RAC)-贝拉前列素钠;贝前列素钠盐(非对映异构体的混合物);贝前列素杂质27;贝前列素杂质10 钠盐;贝前列素钠(非对映体混合物);贝前列素 sodium |
| 英文名称 | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate |
| 英文同义词 | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate;Beraprost sodium (Relative stereochemistry);Beraprost Impurity 10 Sodium Salt;Beraprost impurity 27;Beraprost Sodium (Mixture of Diastereomers);Bera st Sodium Salt(Mixture of Diastereomers) |
| CAS号 | 496807-11-5 |
| 分子式 | C24H31NaO5 |
| 分子量 | 422.5 |
| EINECS号 | |
| 相关类别 | 贝前列素杂质 |
| Mol文件 | 496807-11-5.mol |
| 结构式 | ![sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate 结构式](CAS/20180601/GIF/496807-11-5.gif) |
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate 性质
| 储存条件 | Store at -20°C |
|---|---|
| 溶解度 | 二甲基亚砜：250 mg/mL（594.57 mM） |
| 形态 | 固体 |
| 颜色 | 白色至浅黄色 |
sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate 用途与合成方法
Beraprost sodium 是一种前列环素类似物，是一种稳定且具有口服活性的 PGI2 前药。Beraprost sodium 是有效的血管扩张剂 (vasodilator)，通过扩张肾血管，改善微循环而具有研究肺动脉高压的潜力。
prodrug of PGI2; Vasodilator
Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment leads to a significant increase in the number of tube formation, BPS plays an important role on angiogenic activity. Beraprost sodium (0.1, 1.0, and 10.0 μM; 24 hours) treatment let VE-cadherin at regions of cell–cell contact becomes more abundant and the morphology of endothelial cells tends to be normal compared with those cultured under hypoxia conditions.
Beraprost sodium (oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days) can mitigate the development of renal interstitial fibrosis, decrease renal oxidative stress through its potential vasodilation effect, and further prevent renal interstitial fibrosis.
| Animal Model: | 6-8-week-old C57Bl/6J Male Mice |
| Dosage: | 0.6 mg/kg |
| Administration: | Oral adminstration; 0.6 mg/kg; once daily; 3 or 7 days |
| Result: | Mitigated the development of renal interstitial fibrosis. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026/06/05 | HY-13569A | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Beraprost sodium | 496807-11-5 | 1 mg | 1000元 |
| 2026/06/05 | HY-13569AR | sodium:4-[(1R,2R,3aS,8bS)-2-hydroxy-1-[(E,3S)-3-hydroxy-4-methyloct-1-en-6-ynyl]-2,3,3a,8b-tetrahydro-1H-cyclopenta[b][1]benzofuran-5-yl]butanoate Beraprost sodium (Standard) | 496807-11-5 | 1 mg | 3000元 |